The ARFGEF1 Knockout A-549 Polyclonal Cells are CRISPR/Cas9-edited polyclonal knockout cell populations for disrupting the ARFGEF1 gene in a human lung adenocarcinoma background. This polyclonal pool of A-549 cells carries targeted gene inactivation, enabling functional studies of ARFGEF1 without monoclonal selection. The polyclonal format enables rapid loss-of-function modeling suitable for high-throughput screening and pooled analysis of ARF-dependent phenotypes. Intended for research use, it aids in dissecting the roles of ARFGEF1 in vesicular trafficking, Golgi organization, and cytoskeletal dynamics.
The A-549 host cell line, derived from a lung adenocarcinoma of a 58-year-old male, is a well-characterized adherent epithelial model extensively used in non-small cell lung carcinoma (NSCLC) research, including studies of oncogenic signaling, drug response, and metastasis. These cells retain alveolar epithelial features and serve as a model for studying secretion, migration, and invasion. Combining ARFGEF1 knockout with this cancer-relevant background offers a platform to explore the interplay between membrane trafficking and lung cancer progression.
ARFGEF1 encodes a brefeldin A-sensitive guanine nucleotide exchange factor (GEF) that activates ADP-ribosylation factor (ARF) GTPases, primarily ARF1 and ARF6, by catalyzing GDP-to-GTP exchange. This activation is critical for COPI-mediated vesicle budding at the Golgi, endosomal trafficking, and actin cytoskeleton remodeling. Upstream, ARFGEF1 activity is modulated by phosphatidylinositol 4-phosphate, membrane curvature, and the Golgi-resident protein ACBD3. Activated ARF1-GTP and ARF6-GTP recruit effector proteins such as the COPI complex (including ??-COP), clathrin, GGA1 and GGA2 adaptors, and CASP, thereby orchestrating the formation of transport vesicles and the dynamic organization of actin filaments. Consequently, ARFGEF1 integrates Golgi-to-ER retrograde transport, endocytosis, and actin-mediated cellular processes.
In A-549 cells, ARFGEF1 disruption perturbs Golgi-dependent secretion, endosomal sorting, and actin-based motility??processes frequently hijacked during cancer cell invasion and metastasis. This model enables examination of how alterations in ARF signaling influence lung cancer cell behavior, including secretory pathway output, cell migration, and matrix invasion. Given the links of ARFGEF1 mutations to early infantile epileptic encephalopathy and periventricular heterotopia, this knockout model can also serve as a surrogate system to investigate basic mechanisms of ARF-dependent neuronal migration. Thus, it bridges cancer biology and cellular trafficking research.
Researchers can employ these cells for diverse experimental applications. Western blotting for activated ARF1/ARF6 quantifies ARF activation, while immunofluorescence for Golgi markers (GM130, TGN46) and VSVG-GFP trafficking assays enable real-time analysis of secretory dynamics. Co-immunoprecipitation maps interactions of ARFGEF1 with ??-COP, GGA adaptors, and CASP. Boyden chamber or wound-healing migration/invasion assays, coupled with secretion assays and RNA-seq profiling, delineate functional consequences of ARFGEF1 loss. These applications support mechanistic studies of ARF signaling in cancer and screening of small-molecule modulators of membrane trafficking. For further technical specifications or custom requests, please contact Ascent Research.
